Opko Health Inc. (XCY)

Overview

OPKO Health, Inc. is a diverse healthcare company operating on a global scale, primarily in the diagnostics and pharmaceutical fields. The company has a notable presence in several countries, including the United States, Ireland, Chile, Spain, Israel, Mexico, and beyond. By offering a range of services and products spanning laboratory testing, pharmaceuticals, and therapeutics, OPKO Health aims to address a wide spectrum of health concerns and diseases. Founded in 1991 and based in Miami, Florida, the company continues to expand its influence and capabilities in the healthcare industry, pioneered by a strong commitment to innovation and patient care.

Products and Services

Diagnostic Services:

• BioReference Laboratories: Provides comprehensive laboratory testing services aimed at the detection, diagnosis, evaluation, monitoring, and treatment of diseases. The laboratories specialize in esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare, catering to a broad range of clients including physician offices, clinics, hospitals, employers, and governmental units.
• 4Kscore: A prostate cancer test designed to accurately assess the risk of prostate cancer, aiding in more informed decision-making regarding the necessity for prostate biopsies.

Pharmaceutical Products:

• Rayaldee: Prescription medication developed to treat secondary hyperparathyroidism in patients with stage 3 or 4 chronic kidney disease and vitamin D insufficiency.
• Multi-specific immune therapies: Focused on oncology, infectious diseases, vaccines, and immunology, these therapies are at various stages of development to address unmet medical needs in these areas.
• OPK88004: An orally administered selective androgen receptor modulator that shows promise in therapeutic applications.
• OPK88003: A once-weekly administered peptide intended for the treatment of type 2 diabetes and obesity, addressing major health concerns with an innovative delivery method.
• Somatrogon (hGH-CTP): A once-weekly human growth hormone injection designed to treat growth hormone deficiency with the convenience of less frequent dosing.
• Factor VIIa-CTP: A novel long-acting coagulation factor being developed to treat hemophilia, offering potential benefits over currently available treatments.

Additional Offerings:

• The company is involved in developing and commercializing longer-acting versions of already approved therapeutic proteins, opening new possibilities for treatment regimens.
• Specialty APIs (Active Pharmaceutical Ingredients) production, supporting the broader pharmaceutical industry with high-quality ingredients.
• A diversified portfolio that includes the development, manufacture, and sale of pharmaceutical, nutraceutical, veterinary, and ophthalmic products.
• The commercialization of food supplements and over-the-counter products, addressing a range of health concerns in accessible formats.
• The operation of generics market products, providing cost-effective solutions for various treatment needs.
• Marketing and distribution of a wide range of pharmaceutical products in numerous indications, such as cardiovascular, vaccines, antibiotics, gastrointestinal, hormones, and more across different countries.